Entera Bio AI Stock Analysis
Entera Bio (5DT) AI Stock Analysis
Entera Bio
(Frankfurt:5DT)
No summary available
Entera Bio (5DT) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 541.57M
- Dividend Yield
- ―
- Average Volume (3M)
- 794
- Price to Earnings (P/E)
- -8.0
- Beta (1Y)
- 0.68
- Revenue Growth
- -100.00%
- EPS Growth
- -52.24%
- Country
- Germany
- Employees
- 27
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Entera Bio Business Overview & Revenue Model
Company Description
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experi...
Entera Bio Risk Analysis
Entera Bio disclosed 2 risk factors in its most recent earnings report. Entera Bio reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskEntera Bio Peers Comparison
Overall Rating
NRXP46Neutral
EQ42Neutral
PLRX42Neutral
ATYR33Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $95.59M | -2.95 | 168.68% | ― | ― | 67.07% | |
| 42Neutral | $106.20M | -7.32 | -37.33% | ― | -100.00% | 71.65% | |
| 42Neutral | $43.21M | -0.48 | -58.31% | ― | ― | 49.00% | |
| 33Underperform | $14.97M | -0.28 | -102.46% | ― | -100.00% | 34.89% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:5DT | Entera Bio | 2.86 | 0.58 | 25.44% | |
| ATYR | Atyr Pharma Inc. | 6.11 | -21.10 | -77.56% | |
| NRXP | Nrx Pharmaceuticals, Inc. | 2.19 | 0.08 | 3.79% | |
| EQ | Equillium | 1.29 | 0.24 | 22.86% | |
| PLRX | Pliant Therapeutics, Inc. | 0.70 | -0.95 | -57.76% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
